Takeda 205

Purpose

To assess the safety and effectiveness of treatment with daily oral administration of dexlansoprazole 30 or 60 mg for 8 to 12 weeks in pediatric subjects aged 1 to 11 years, inclusive, with Erosive Esophagitis.

Criteria

Pediatric subjects aged 1 to 11 years, inclusive, with Erosive Esophagitis

Details

Subjects 1-11 years old with Erosive Esophagitis will be enrolled in the study.  Subjects will undergo an Endoscopy and will have lab tests at most visits

Interested in more information? Contact Us:

Sunny Hussain, M.D., Principal Investigator
(318) 212-8130

IRB: Willis-Knighton
IRB Number:
Trial Type: Drug
Sponsor: Takeda